stockrowCue Biopharma, Inc.
CUECue Biopharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $27.5 million, up 195.7% from fiscal 2024.
- Revenue
- +166.7%
- EPS
- −793.2%
- Free cash flow
- −742.7%
Quarter to June 2026, against a year earlier
Follow CUE
Alert me
Cue Biopharma, Inc. (CUE) EV/Sales
As of 6 November 2026, Cue Biopharma, Inc. (CUE) trades at a EV/Sales of 2.7×. Over the past ten years it has ranged from −0.1× (September 2024) to 377× (May 2023); the current reading is higher than 22% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.2× | (94.96%) |
| FY2024 | 4.7× | (70.18%) |
| FY2023 | 15.7× | (31.10%) |
| FY2022 | 22.9× | 14.12% |
| FY2021 | 20.0× | (77.51%) |
| FY2020 | 89.0× | 4.03% |
| FY2019 | 85.6× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 4.9× | 822.02% |
| Mar 2026 | 0.5× | 124.33% |
| Dec 2025 | 0.2× | (96.87%) |
| Sep 2025 | 7.6× | 57.41% |
| 29 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CMPX Compass Therapeutics, Inc. compare | n/m |
| ADAG Adagene Inc. Sponsored ADR compare | n/m |
| TARA Protara Therapeutics, Inc. compare | n/m |
| PDSB PDS Biotechnology Corporation compare | n/m |
| MSLE Satellos Bioscience Inc. compare | n/m |
| CUE Cue Biopharma, Inc. | 2.7× |
| SPRB Spruce Biosciences, Inc. compare | 4.9× |
| MOLN Molecular Partners AG Sponsored ADR compare | 9.3× |
| YARW Yarrow Bioscience, Inc compare | 118× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)